

AMENDMENTS TO THE CLAIMS

1-7. (Canceled)

8. (Previously Presented) A peptide compound which selectively binds to the extracellular portion of human PSMA consisting of the amino acid sequence set forth as SEQ ID NO:1.

9-27. (Canceled)

28. (Currently Amended) A peptide compound which selectively binds to the extracellular portion of human PSMA and comprises at least 5 residues of the consensus sequence QKHHNYL (SEQ ID NO:109), and wherein the peptide is 9 amino acid residues in length wherein the 5 residues are within a linear span of 7 amino acid residues.

29. (Currently Amended) The peptide of claim 28, wherein the peptide has at least 6 residues of the consensus sequence QKHHNYL (SEQ ID NO:109), and wherein the peptide is 9 amino acid residues in length wherein the 6 residues are within a linear span of 7 amino acid residues.

30. (Previously Presented) The peptide of claim 28, wherein the peptide has the consensus sequence QKHHNYL (SEQ ID NO:109).

31. (Cancelled)

32. (Previously Presented) The peptide of claim 28 or 31, wherein the peptide comprises a cysteine residue at the N and C terminus.

33. (Previously Presented) The peptide of claim 32, wherein the peptide is cyclic.

34. (Currently Amended) The peptide of claim 28, wherein the peptide comprises one or more amino acid analogues which mimics the chemical structure of the peptide and retains the ability to bind PSMA or a PSMA expressing cell.